Paris, France and Camberley, UK – 12 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 11 November 2020.
Graham Mullis, Chief Executive of the Company, acquired 60,875 ordinary shares of €1/15 each in the Company at a price of £8.17 per share. The resultant beneficial shareholding of Mr Mullis is 122,506 ordinary shares representing 0.17% of the Company’s issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Graham Mullis, Chief Executive Officer
|
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
See 1(a) – classified as a PDMR of the Company
|
||||
|
b) |
Initial notification/ Amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Novacyt S.A. |
||||
|
b) |
LEI |
213800BWAC2BF295EG28 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
ordinary shares of €1/15 each
|
||||
|
Identification code |
FR0010397232 |
|||||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
|
||||
|
e) |
Date of the transaction |
11 November 2020 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
||||
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
